Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Icanbelimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Suzhou Connect Biopharmaceuticals
- 01 Jun 2023 According to a Connect Biopharma Australia media release, study is conducted over 60 sites in 4 countries.
- 01 Jun 2023 According to a Connect Biopharma Australia media release, the company plan to submit the full data from the study to a medical congress later this year.
- 01 Jun 2023 Positive Long-Term Data (Week 48) presented in the Connect Biopharma Australia Media Release.